Clinical Trial

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Study acronym: LUMINA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-06-24
notable Trial sites reduced: 26 -> 10 locations 2026-06-24
Trial Details
NCT Number NCT07053800
Lead Sponsor Autolus Limited
Collaborators: PPD Development, LP
Conditions Lupus Nephritis
Enrollment 35 participants
Start Date 2026-01-16
Primary Completion 2028-08 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-31